Towards precision therapy in HER2-positive early-stage breast cancer

Towards precision therapy in HER2-positive early-stage breast cancer

Saved in:

Bibliographic Details
Main Authors:	Serena Di Cosimo, Paolo Verderio
Format:	Article
Language:	English
Published:	Elsevier 2025-06-01
Series:	Breast
Online Access:	http://www.sciencedirect.com/science/article/pii/S0960977625004783
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Target therapy in treatment of HER2-positive breast cancer
by: A. S. Belokhvostova, et al.
Published: (2016-02-01)

POSSIBILITIES OF THERAPY OF HER-2-POSITIVE REGIONAL BREAST CANCER
by: A. S. Belokhvostova, et al.
Published: (2015-04-01)

A strain-guided trial of cardioprotection in early-stage breast cancer patients on anti-HER2 therapy (PROTECT HER2)
by: Fei Fei Gong, et al.
Published: (2024-11-01)

Identification of new selective CD36 inhibitors to potentiate HER2-targeted therapy in HER2-positive breast cancer
by: Lorenzo Castagnoli, et al.
Published: (2025-08-01)

HER-2-positive metastatic breast cancer: new possibilities for therapy
by: E. V. Artamonova, et al.
Published: (2014-07-01)

A glimpse into the future: Integrating artificial intelligence for precision HER2‐positive breast cancer management
by: Xinpei Deng, et al.
Published: (2024-09-01)

EXPERIENCE OF USING PERTUZUMAB IN ANTICANCER THERAPY FOR HER2-POSITIVE BREAST CANCER
by: O. I. Kit, et al.
Published: (2021-05-01)

CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer
by: Lorenzo Castagnoli, et al.
Published: (2025-01-01)

Role of targeted therapy in the treatment of HER-2-positive breast cancer brain metastases
by: G. A. Dashyan, et al.
Published: (2016-06-01)

ANCA-positive pulmonary granulomatosis in a HER2-positive breast cancer patient on anti-HER2 therapy: case report and literature review
by: Florian Collard Vanthournhout, et al.
Published: (2025-05-01)

Correction: CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer
by: Lorenzo Castagnoli, et al.
Published: (2025-05-01)

Small HER2 positive breast cancer: When is enough?
by: Randeep Singh, et al.
Published: (2018-01-01)

Recent Research Advances in HER2-Positive Breast Cancer Concerning Targeted Therapy Drugs
by: Junmin Li, et al.
Published: (2025-07-01)

The Rapidly Changing Treatment Landscape of Systemic Therapy for HER-2 Positive Metastatic Breast Cancer
by: Larissa Russo-Vorms, et al.
Published: (2021-10-01)

Genomic characterization of the HER2-enriched intrinsic molecular subtype in primary ER-positive HER2-negative breast cancer
by: Lennart Hohmann, et al.
Published: (2025-03-01)

Precise HER2 Protein Degradation via Peptide‐Conjugated Photodynamic Therapy for Enhanced Breast Cancer Immunotherapy
by: Changyong Guo, et al.
Published: (2025-01-01)

Subtype-specific prognostic impact of Bcl-2 in HER2-positive and HER2-negative breast cancer
by: Taeyeong Kim, et al.
Published: (2025-01-01)

Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2-Positive Breast Cancer
by: Iris Otoya, et al.
Published: (2024-01-01)

STUDY OF THE EFFECT OF LOMUSTIN ON HER2-POSITIVE BREAST CANCER IN FVB/N HER-2 TRANSGENIC MICE
by: A. N. Stukov, et al.
Published: (2019-11-01)

Beyond HER2-Positive: The ADC Revolution in Breast Cancer Care
by: Marucs Vetter
Published: (2025-06-01)

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
by: Fatima Cardoso, et al.
Published: (2024-12-01)

Genetic Alterations in HER2-Positive and Equivocal Breast Cancer by Immunohistochemistry
by: Tsai YF, et al.
Published: (2025-03-01)

Fourth Swiss Annual Meeting on HER2-Positive Breast Cancer: Antibody-Drug Conjugates in HER2-Positive Disease and Beyond
by: Marcus Vetter, et al.
Published: (2025-06-01)

Sequence of therapy impact on older women with comorbidities and triple-negative or HER2-positive breast cancer
by: Nina Tamirisa, et al.
Published: (2025-02-01)

Echo-loop of subclinical cardiovascular toxicity in women associated with HER2-positive breast cancer therapy
by: I. V. Pershukov, et al.
Published: (2024-07-01)

Clinical characteristics, treatment, and survival of thrombocytopenia induced by T-DM1 in early HER2-positive breast cancer
by: Fang Wang, et al.
Published: (2025-07-01)

Present and future of breast cancer anti-Her-2-therapy
by: V. P. Letyagin
Published: (2014-07-01)

Improving treatment outcomes for patients with HER2‑positive breast cancer using neoadjuvant double HER2 blockade
by: V. F. Semiglazov, et al.
Published: (2024-11-01)

PAK5 promotes the trastuzumab resistance by increasing HER2 nuclear accumulation in HER2-positive breast cancer
by: Xin Zhao, et al.
Published: (2025-04-01)

Prognostic difference between early breast cancer patients with HER2 low and HER2 zero status
by: Chihwan David Cha, et al.
Published: (2025-03-01)

HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
by: Tamera J. Lillemoe, et al.
Published: (2021-01-01)

Current approaches to the treatment of HER2‑positive breast cancer with brain metastases
by: T. Yu. Semiglazova, et al.
Published: (2021-06-01)

The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer
by: Chaokun Wang, et al.
Published: (2021-05-01)

Exploring the full potential of Pyrotinib in HER2-positive metastatic breast cancer
by: Wei-Zhen Tang, et al.
Published: (2025-08-01)

Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer
by: Manikandan Dhanushkodi
Published: (2019-01-01)

Prognostic Significance of Delays in Initiation of Adjuvant Trastuzumab-Based Therapy in Patients with HER2-Positive Breast Cancer
by: Gavin P. Dowling, et al.
Published: (2025-05-01)

Combination chemotherapy and hormone therapy in patients with hormone receptor positive and HER2 negative metastatic breast cancer
by: Kripa Bajaj, et al.
Published: (2025-08-01)

Antibody-functionalized iron-based nanoplatform for ferroptosis-augmented targeted therapy of HER2-positive breast cancer
by: Jingchao Gao, et al.
Published: (2025-10-01)

Involvement of microRNAs-449/FASN axis in response to trastuzumab therapy in HER2-positive breast cancer
by: Ana Lameirinhas, et al.
Published: (2025-03-01)

Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer
by: Joyce O'Shaughnessy, et al.
Published: (2025-06-01)